Human glioblastoma in mouse


The following includes a selection of recent publications from our lab.

IFN-γ- and IL-17-producing CD8+ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity.

Ohkuri T, Kosaka A, Ikeura M, Salazar AM, Okada H. 

J Immunother Cancer. 2021 Jun 1; 9(6):e002426. doi: 10.1136/jitc-2021-002426. PMID: 34193567; PMCID: PMC8246372.
PubMed Link >

Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice.

Chuntova P, Hou Y, Naka R, Yamamichi A, Chen T, Goretsky Y, Hatae R, Nejo T, Kohanbash G, Mende AL, Montoya M, Downey KM, Diebold D, Skinner J, Liang HE, Schwer B, Okada H. 

Neuro Oncol. 2021 Aug 4; doi: 10.1093/neuonc/noab182..
PubMed Link >
Cover of Science Translational Medicine, April 2021

SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma

Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, Downey KM, Yu W, Carrera DA, Celli A, Cho J, Briones JD, Duecker JM, Goretsky YE, Dannenfelser R, Cardarelli L, Troyanskaya O, Sidhu SS, Roybal KT, Okada H, Lim WA.

Sci Transl Med. 2021 Apr 28; 13 (591): eabe7378. doi: 10.1126/scitranslmed.abe7378.
PubMed Link >

Tumor antigens in glioma.

Nejo T, Yamamichi A, Almeida ND, Goretsky YE, Okada H.

Semin Immunol. . 2020 Feb 6; 47: 101385. doi: 10.1016/j.smim.2020.101385.
PubMed Link >

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.

Chuntova P, Downey KM, Hegde B, Almeida ND, Okada H.

Front Immunol. 2019 Jan 22; 9: 3062. doi: 10.3389/fimmu.2018.03062.
PubMed Link >

Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas

Müller S, Agnihotri S, Shoger KE, Myers MI, Smith N, Chaparala S, Villanueva CR, Chattopadhyay A, Lee AV, Butterfield LH, Diaz A, Okada H, Pollack IF, Kohanbash G.

JCI Insight. 2018 Apr 5; 3 (7): 98791. doi: 10.1172/jci.insight.98791. [Epub ahead of print].
PubMed Link >

Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy

Chheda ZS, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, Yang X, Carrera DA, Downey KM, Shrivastav S, Liu S, Lin Y, Lagisetti C, Chuntova P, Watchmaker PB, Mueller S, Pollack IF, Rajalingam R, Carcaboso AM, Mann M, Sette A, Garcia, KC, Hou Y and Okada H.

J Exp Med. 2018 Jan 2; 215 (1): 141-157. doi: 10.1084/jem.20171046. Epub 2017 Dec 4.
PubMed Link >

Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment

Müller S, Kohanbash G, Liu SJ, Alvarado B, Carrera D, Bhaduri A, Watchmaker PB, Yagnik G, Di Lullo E, Malatesta M, Amankulor NM, Kriegstein AR, Lim DA, Aghi M, Okada H, Diaz A.

Genome Biol. 2017 Dec 20; 18 (1): 234. doi: 10.1186/s13059-017-1362-4.
PubMed Link >

Fluorine-19 nuclear magnetic resonance of chimeric antigen receptor T cell biodistribution in murine cancer model

Chapelin F, Gao S, Okada H, Weber TG, Messer K, Ahrens ET.

Sci Rep. 2017 Dec 18; 7 (1): 17748. doi: 10.1038/s41598-017-17669-4.
PubMed Link >

Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma

Dutoit V, Migliorini D, Ranzanici G, Marinari E, Widmer V, Lobrinus JA, Momjian S, Costello J, Walker PR, Okada H, Weinschenk T, Herold-Mende C, Dietrich PY. 

Oncoimmunology. 2017 Nov 7; 7 (2): e1391972. doi: 10.1080/2162402X.2017.1391972. eCollection 2018.
PubMed Link >

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV.

Sci Transl Med. 2017 Jul 19; 9 (399): eaaa0984. doi: 10.1126/scitranslmed.aaa0984.
PubMed Link >

Is the immune response a friend or foe for viral therapy of glioma?

Okada H, Thorne SH.

Neuro Oncol. 2017 Jul 1; 19 (7): 882-883. doi: 10.1093/neuonc/nox082.
PubMed Link >

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, Chheda ZS, Downey KM, Watchmaker PB, Beppler C, Warta R, Amankulor NA, Herold-Mende C, Costello JF, Okada H.

J Clin Invest. 2017 Apr 3; 127 (4): 1425-1437. doi: 10.1172/JCI90644. Epub 2017 Mar 20.
PubMed Link >

Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors: Initial Experience

Furtado AD, Ceschin R, Blüml S, Mason G, Jakacki RI, Okada H, Pollack IF, Panigrahy A.

Neuroimaging Clin N Am. 2017; 27 (1): 155-166. doi: 10.1016/j.nic.2016.09.002.
PubMed Link >

Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study

Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H. 

J Neurooncol. 2016; 130 (3): 517-527. Epub 2016 Sep 13.
PubMed Link >